Dr. Troy O Maydew, OD Optometrist Medicare: Accepting Medicare Assignments Practice Location: 216 S Oak St, Pratt, KS 67124 Phone: 620-672-5934 Fax: 620-672-3550 |
Dr. Seth Alan Thibault, OD Optometrist Medicare: Accepting Medicare Assignments Practice Location: 216 S Oak St, Pratt, KS 67124 Phone: 620-672-5934 Fax: 620-672-3550 |
Dr. Phil Douglas Farmer, OD Optometrist Medicare: Not Enrolled in Medicare Practice Location: 203 Watson St, Pratt, KS 67124 Phone: 620-672-5934 Fax: 620-672-3550 |
Maydew Thibault Optometry Llc Optometrist Medicare: Medicare Enrolled Practice Location: 216 S Oak St, Pratt, KS 67124 Phone: 620-672-5934 Fax: 620-672-3550 |
News Archive
Millennium: The Takeda Oncology Company and, Takeda Pharmaceutical Company Limited today announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has issued a positive opinion for conditional approval of brentuximab vedotin for two indications.
Physicians at La Fe University and Polytechnic Hospital - Valencia presented their early clinical outcome data on the use of Esteya electronic brachytherapy for the treatment of basal cell carcinoma in a paper in the current issue of Journal of Contemporary Brachytherapy. The ongoing study showed 100 percent complete response and excellent cosmetic outcome in all lesions treated to date with Esteya.
With 1 in 5 overweight Americans suffering from chronic kidney disease, Cleveland Clinic researchers analyzed the nutritional and lifestyle habits of overweight adults, finding that their methods included diets and diet pills that may cause further kidney damage.
Using an engineered common cold virus, UCLA researchers delivered a genetic payload to prostate cancer cells that allowed them, using Positron Emission Tomography (PET), to locate the diseased cells as they spread to the lymph nodes, the first place prostate cancer goes before invading other organs.
MANY patients whose lung cancer is diagnosed as an emergency in hospital reported difficulties in previously seeing their GP, according to research presented at the National Cancer Research Institute (NCRI) Cancer Conference in Liverpool today (Tuesday).
› Verified 9 days ago